Cystic Fibrosis

Patients ages 2 to 5 years now eligible for the triple therapy

Presented with classic signs and symptoms, but still not tested

Accelerating trial enrollment can catalyze access to much-needed medications

Other frequent cardiac comorbidities included Afib and acute MI, real-world analysis shows

Also in TTHealthWatch: a new way to diagnose idiopathic pulmonary fibrosis

Also in TTHealthWatch: Changing guidelines for prediabetes and diabetes screening

Another group of CF patients sees a win for triple therapy in phase III trial

Health news and commentary from around the Web gathered by the MedPage Today staff

Bioethicist and pediatrician debate cystic fibrosis gene-editing

Quotable quotes from MedPage Today's sources

CMS competitive bidding for durable medical equipment to blame, experts say

Study shows that randomized trials are feasible among those under 4 months

A researcher-patient's plea for broader inclusion in cystic fibrosis trials

Tested as standalone, but potential role seen as add-on therapy